JENNIFER EVANS: Open Payments
NPI 1063781532 · MICHIGAN CITY, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$471 in 19 payments from 7 companies in 2025. Trend: 2023 $680 · 2024 $185 · 2025 $471
Food & beverage: $471
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 5 | $182 |
| E.R. Squibb & Sons, L.L.C. | 6 | $108 |
| ABBVIE INC. | 2 | $58 |
| Otsuka America Pharmaceutical, Inc. | 3 | $57 |
| Supernus Pharmaceuticals, Inc. | 1 | $28 |
| Corium, LLC | 1 | $24 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $15 |
Products named: UZEDY, COBENFY, VRAYLAR, REXULTI, Qelbree, ABILIFY ASIMTUFII, Azstarys, CAPLYTA.
Industry payments across IN — which companies pay providers there.
